330 related articles for article (PubMed ID: 27146751)
21. A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
Suleiman AA; Frechen S; Scheffler M; Zander T; Nogova L; Kocher M; Jaehde U; Wolf J; Fuhr U
AAPS J; 2015 Nov; 17(6):1483-91. PubMed ID: 26286677
[TBL] [Abstract][Full Text] [Related]
22. A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.
Biswas B; Ghadyalpatil N; Krishna MV; Deshmukh J
Indian J Cancer; 2017 Dec; 54(Supplement):S55-S64. PubMed ID: 29292709
[TBL] [Abstract][Full Text] [Related]
23. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
24. [Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)].
Iwata K; Ryota N; Hikita A; Sando M; Suzuki H; Tamiya M; Azuma Y; Tani E; Hamaguchi M; Tanaka A; Shiroyama T; Morishita N; Okamoto N; Futagami S; Hirashima T
Gan To Kagaku Ryoho; 2015 Aug; 42(8):967-72. PubMed ID: 26321711
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.
Zaarour M; Weerasinghe C; Nazha B; Hassan S; Atallah JP
Expert Rev Anticancer Ther; 2015; 15(11):1327-36. PubMed ID: 26414352
[TBL] [Abstract][Full Text] [Related]
28. Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients.
Shepherd FA
Clin Adv Hematol Oncol; 2016 Jan; 14(1):41-3. PubMed ID: 27057666
[TBL] [Abstract][Full Text] [Related]
29. Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations.
Riely GJ
Clin Adv Hematol Oncol; 2016 Jan; 14(1):41, 44-5. PubMed ID: 27057667
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
[TBL] [Abstract][Full Text] [Related]
31. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
32. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
[TBL] [Abstract][Full Text] [Related]
33. Safety of gefitinib in non-small cell lung cancer treatment.
Hsiue EH; Lee JH; Lin CC; Yang JC
Expert Opin Drug Saf; 2016 Jul; 15(7):993-1000. PubMed ID: 27212579
[TBL] [Abstract][Full Text] [Related]
34. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience on use of oral EGFR-TKIs as first-line treatment of advanced NSCLC from a tertiary care centre in North India and implications of skin rash.
Singh N; Vishwanath G; Aggarwal AN; Behera D
Indian J Chest Dis Allied Sci; 2014; 56(3):149-52. PubMed ID: 25823108
[TBL] [Abstract][Full Text] [Related]
36. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
[TBL] [Abstract][Full Text] [Related]
38. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Burotto M; Ali SA; O'Sullivan Coyne G
Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
[TBL] [Abstract][Full Text] [Related]
39. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
40. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]